Vir Biotechnology to Unveil Latest Hepatitis Delta Trial Data
Vir Biotechnology will present expanded Phase 2 SOLSTICE trial results evaluating the combination treatment of elebsiran and tobevibart for chronic hepatitis delta at the American Association for the Study of Liver Diseases conference in Denver. The presentation will take place November 5-9, 2026, providing updated efficacy data for this therapeutic combination.
Vir Biotechnology is advancing its work on a serious liver disease with limited treatment options. Hepatitis delta is a particularly challenging infection that occurs only in patients already infected with hepatitis B, making it a difficult-to-treat population. The company's approach combines two investigational drugs designed to address the infection through different mechanisms.
The SOLSTICE trial represents a key milestone in evaluating whether this two-drug strategy can effectively manage the chronic condition. Results from expanded Phase 2 testing will help determine whether the combination warrants further development and eventual regulatory review for patient access.
Hepatitis delta affects a relatively small but vulnerable patient population globally, primarily in developing regions. Positive trial outcomes could expand therapeutic options for a condition with few approved treatments, potentially improving disease management and slowing progression to liver damage. However, development of new drugs typically requires years before potential availability, and trial success does not guarantee eventual regulatory approval or market access for patients in all regions.